Glaucoma filtration surgery following sustained elevation of intraocular pressure secondary to intravitreal anti-VEGF injections
| Autor: | Ashish Agar, Allan Bank, I-Van Ho, Simon E. Skalicky |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Male
Vascular Endothelial Growth Factor A medicine.medical_specialty Intraocular pressure genetic structures Bevacizumab medicine.medical_treatment Glaucoma Angiogenesis Inhibitors Trabeculectomy Antibodies Monoclonal Humanized Macular Degeneration Ophthalmology Ranibizumab medicine Humans Antihypertensive Agents Intraocular Pressure Aged Retrospective Studies Aged 80 and over business.industry Retrospective cohort study Middle Aged medicine.disease eye diseases Choroidal Neovascularization Filtration surgery Intravitreal Injections Female Ocular Hypertension sense organs Complication business Glaucoma Open-Angle medicine.drug |
| Zdroj: | Ophthalmic surgery, lasersimaging : the official journal of the International Society for Imaging in the Eye. 43(4) |
| ISSN: | 1938-2375 |
| Popis: | BACKGROUND AND OBJECTIVE: To document cases of sustained elevation of intraocular pressure (IOP) while receiving intravitreal anti-vascular endothelial growth factor (VEGF) agents and subsequent management. PATIENTS AND METHODS: A retrospective series of all cases managed by the authors and colleagues was performed. RESULTS: Six patients developed sustained elevated IOP; five received ranibizumab and one bevacizumab. Four received unilateral and two received bilateral injections. Two had preexisting primary open-angle glaucoma and one had pseudoexfoliative glaucoma, all with stable IOP prior to anti-VEGF treatment. Angles were open in all cases. Peak IOP averaged 43 mm Hg (range: 34 to 60 mm Hg). The mean number of injections preceding the IOP increase was 10 (range: 1 to 20). Four patients required trabeculectomy, one selective laser trabeculoplasty, and one multiple topical medications. CONCLUSION: A sustained increase in IOP requiring glaucoma filtering surgery is a rare but important treatment complication for patients receiving intravitreal anti-VEGF therapy, especially those with preexisting glaucoma or glaucoma risk factors. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|